References
- Stuerenburg HJ, Schoser BG. Acute overdosage and intoxication with carbidopa/levodopa can be detected in the subacute stage by measurement of 3-o-methyldopa. J Neurol Neurosurg Psychiatry 1999; 67: 122–123
- Sporer KA. Carbidopa-levodopa overdose. Am J Emerg Med 1991; 9: 47–48
- Hoehn MM, Rutledge CO. Acute overdose with levodopa. Clinical and biochemical consequences. Neurology 1975; 25: 792–794
- Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969; 280: 337–45
- Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of a nine years’ experience. Can Med Assoc J 1969; 101: 59–68
- Yahr MD, Duvoisin RC, Schear MJ, et al. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343–354
- Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 7: 35–49
- Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971; 46: 231–239
- Tolosa E, Marti MJ, Valldeoriola F, Molinuevo JL. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998; 50(suppl 6)2–10
- Yeh KC, August TF, Bush DF, Lasseter KC, et al. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989; 39(suppl 2)25–37
- Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989; 39(suppl 2)38–44